Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.
Type:
Grant
Filed:
October 27, 2014
Date of Patent:
September 3, 2019
Assignee:
Inhibrx, LP
Inventors:
Brendan P. Eckelman, John C. Timmer, Quinn Deveraux
Abstract: This invention relates generally to monoclonal antibodies that recognize CD47, more specifically to CD47 antibodies that do not cause a significant level of agglutination of cells, to methods of generating these antibodies, and to methods of using these monoclonal antibodies as therapeutics.
Type:
Grant
Filed:
April 29, 2015
Date of Patent:
May 30, 2017
Assignee:
InhibRx, LP
Inventors:
Brendan Eckelman, John Timmer, Amir Razai, Quinn Deveraux, Kyle Jones, Peter L. Nguy